Cipla Builds On Albuterol Share As Investors Await FY23 US Revenue Delta
No Definitive Decision Yet On Avenue Deal
Cipla signals more US momentum with headroom for albuterol market share expansion, promising prospects for generic Brovana and strong launch line-up in FY23, but analysts also keep close eye on regulatory pre-approval inspection timelines.
You may also be interested in...
Having previously seen patent litigation with originator Chiesi dismissed, Lupin has realized plans to launch the first UK generic version of Fostair (beclometasone/formoterol), with the potential significant cost savings” for the UK’s National Health Service.
Endo’s Par looks set to provide much needed supply in the US market for varenicline tablets, after originator Pfizer ran into supply and distribution problems due to the presence of a nitrosamine for its Chantix original.
After Lupin’s launch of an authorized generic, Cipla has entered the US market with its own generic rival to Sunovion’s Brovana, after receiving the FDA approval for the inhalation solution. Axar Pharma and Glenmark also currently hold approvals and Teva a tentative approval for arformoterol tartrate abbreviated new drug applications.